This 2022 review article, published in Expert Review of Anticancer Therapy by Wai M. Liu and Angus G. Dalgleish, explores the potential of low-dose naltrexone (LDN) as an adjunctive treatment in oncology. The authors discuss how LDN, administered at doses significantly lower than those used for addiction treatment, may exert
